Jill Hallin
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)Mirati Therapeutics (United States)(US)Fate Therapeutics (United States)(US)
Publications by Year
Research Areas
Cancer-related gene regulation, Lung Cancer Treatments and Mutations, Biochemical and Molecular Research, Protein Kinase Regulation and GTPase Signaling, Chemical Reactions and Isotopes
Most-Cited Works
- → The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients(2019)1,248 cited
- → Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor(2021)660 cited
- → Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer(2020)572 cited
- → Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor(2022)475 cited
- → Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer(2022)339 cited
- → Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1(2008)226 cited